



## Promising Safety, Tolerability and Efficacy Results from Morria Biopharmaceuticals' MRX-4 Phase II Study in Allergic Rhinitis to be Presented at the upcoming EAACI Congress



Press Release Source: Morria Biopharmaceuticals Plc On Thursday June 3, 2010, 9:05 am EDT

LONDON & NEW YORK--(BUSINESS WIRE)--Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4 (n=105) in patients suffering from allergic rhinitis at the upcoming 29<sup>th</sup> EAACI Congress (European Academy of Allergy and Clinical Immunology) in London on June 7<sup>th</sup>. The results will be presented by the study's principal investigator Prof. Eric Bateman.

The Nasal Allergen Challenge (NAC) study was conducted in allergic rhinitis patients outside of the local allergy season. The double blind placebo-controlled study consisted of a six-day, twice-daily intranasal administration of placebo or MRX-4 followed by an intranasal dose of allergen on the morning of the seventh day with a clinical follow-up and scoring over the next 24 hours. Blood, urine and pharmacokinetics (PK) analyses were also conducted.

The primary end-point of the study was safety with standard physiological and biochemical measurements taken and monitored. The secondary end-points of the study consisted of monitoring levels of inflammatory mediators (IL-5, IL-13, MCP-1, TNF-alpha, IL-8 and Eotoxin) as well as eosinophils in the nasal lavage and assessing MRX-4 clinical efficacy by monitoring clinical categories such as rhinorrhea, nasal itching, sneezing, frontal headache, nasal congestion and ear/palate itching.

### ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel, anti-inflammatory pharmaceuticals termed multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known anti-inflammatory drug target. At the same time, they also enrich the cell surface glycosaminoglycans thereby protecting the cell against inflammatory agents. Morria is determined to become a pivotal player in the anti-inflammatory drug market by developing and commercializing novel drugs for respiratory, dermatology, pulmonary, gastro-intestinal and allergic inflammatory diseases. For more information, please visit <http://www.morria.com>.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - Persons in the business of disseminating information.

---

### Contact:

Morria Biopharmaceuticals Plc  
Yuval Cohen, President  
T: +44 (0)207 152 6341  
E: [info@morria.com](mailto:info@morria.com)  
W: <http://www.morria.com>

Copyright © 2010 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials by posting, archiving in a public web site or database, or redistribution in a computer network is strictly forbidden.